The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
Open accessAbstract
BACKGROUND: Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS: We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patients infected with HIV-1 that has triple-class drug resistance in whom antiretroviral therapy had failed. Patients were randomly assigned to raltegravir or placebo in a 2:1 ratio. RESULTS: In the combined studies, 699 of 703 randomized patients (462 and 237 in the raltegravir and placebo groups, respectively) received the study drug. Seventeen of the 699 patients (2.4%) discontinued the study before week 16. Discontinuation was related to the study treatment in 13 of these 17 patients: 7 of the 462 raltegravir recipients (1.5%) and 6 of the 237 placebo recipients (2.5%). The results of the two studies were consistent. At week 16, counting noncompletion as treatment failure, 355 of 458 raltegravir recipients (77.5%) had HIV-1 RNA levels below 400 copies per milliliter, as compared with 99 of 236 placebo recipients (41.9%, P<0.001). Suppression of HIV-1 RNA to a level below 50 copies per milliliter was achieved at week 16 in 61.8% of the raltegravir recipients, as compared with 34.7% of placebo recipients, and at week 48 in 62.1% as compared with 32.9% (P<0.001 for both comparisons). Without adjustment for the length of follow-up, cancers were detected in 3.5% of raltegravir recipients and in 1.7% of placebo recipients. The overall frequencies of drug-related adverse events were similar in the raltegravir and placebo groups. CONCLUSIONS: In HIV-infected patients with limited treatment options, raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks. (ClinicalTrials.gov numbers, NCT00293267 and NCT00293254.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Grulich, A. E., van Leeuwen, M. T., Falster, M. O., & Vajdic, C. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61050-2 · Cited by 2,323
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells
Hazuda, D. J., Felock, P., Witmer, M., Wolfe, A., Stillmock, K., Grobler, J. A., Espeseth, A., Gabryelski, L., Schleif, W., Blau, C., et al. (2000) · Science · doi:10.1126/science.287.5453.646 · Cited by 1,131
Self-citationTreatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationEnfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Self-citationTreatment for Adult HIV Infection: 2004 Recommendations of the International AIDS Society-USA Panel
Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C. J., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., et al. (2004) · JAMA · doi:10.1001/jama.292.2.251 · Cited by 737
Self-citationEfficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Self-citationGrinsztejn, B., Nguyen, B.-Y., Katlama, C., Gatell, J. M., Lazzarin, A., Vittecoq, D., Gonzalez, C. J., Chen, J., Harvey, C. M., & Isaacs, R. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60597-2 · Cited by 574
Self-citationLi, T., Tubiana, R., Katlama, C., Calvez, V, Mohand, H. A., & Autran, B. (1998) · The Lancet · doi:10.1016/s0140-6736(97)10291-4 · Cited by 544
Self-citationMadruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., Pialoux, G., Wilkin, T., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61047-2 · Cited by 517
Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
Cooper, D. A., Steigbigel, R. T., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Kumar, P. N., Eron, J. E., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708978 · Cited by 509
Self-citationThe Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508
The prevalence of antiretroviral drug resistance in the United States
Richman, D. D., Morton, S. C., Wrin, T., Hellmann, N., Berry, S., Shapiro, M. F., & Bozzette, S. A. (2004) · AIDS · doi:10.1097/01.aids.0000131310.52526.c7 · Cited by 408
Markowitz, M., Nguyen, B.-Y., Gotuzzo, E., Mendo, F., Ratanasuwan, W., Kovacs, C., Prada, G., Morales-Ramirez, J. O., Crumpacker, C. S., Isaacs, R. D., et al. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318157131c · Cited by 408
Self-citationLazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., Towner, W., Trottier, B., Peeters, M., Vingerhoets, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61048-4 · Cited by 392
Self-citationMarkowitz, M., Morales-Ramirez, J. O., Nguyen, B.-Y., Kovacs, C. M., Steigbigel, R. T., Cooper, D. A., Liporace, R., Schwartz, R., Isaacs, R., Gilde, L. R., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31802b4956 · Cited by 368
Self-citationRatnam, I., Chiu, C., Kandala, N. B., & Easterbrook, P. J. (2006) · Clinical Infectious Diseases · doi:10.1086/499356 · Cited by 355
Immune Reconstitution in HIV‐Infected Patients
Hirsch, H. H., Kaufmann, G., Sendi, P., & Battegay, M. (2004) · Clinical Infectious Diseases · doi:10.1086/383034 · Cited by 327
Espeseth, A. S., Felock, P., Wolfe, A., Witmer, M., Grobler, J., Anthony, N., Egbertson, M., Melamed, J. Y., Young, S., Hamill, T., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200139397 · Cited by 317
Self-citationIntegrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques
Hazuda, D. J., Young, S. D., Guare, J. P., Anthony, N. J., Gomez, R. P., Wai, J. S., Vacca, J. P., Handt, L., Motzel, S. L., Klein, H. J., et al. (2004) · Science · doi:10.1126/science.1098632 · Cited by 285
Self-citationKassahun, K., McIntosh, I., Cui, D., Hreniuk, D., Merschman, S., Lasseter, K., Azrolan, N., Iwamoto, M., Wagner, J. A., & Wenning, L. A. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016196 · Cited by 278
Combination Antiretroviral Therapy and Recent Declines in AIDS Incidence and Mortality
Vittinghoff, E., Scheer, S., O'Malley, P., Colfax, G., Holmberg, S. D., & Buchbinder, S. P. (1999) · The Journal of Infectious Diseases · doi:10.1086/314623 · Cited by 275
Gulick, R. M., Su, Z., Flexner, C., Hughes, M. D., Skolnik, P. R., Wilkin, T. J., Gross, R., Krambrink, A., Coakley, E., Greaves, W. L., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/518797 · Cited by 239
Impact of drug resistance mutations on virologic response to salvage therapy
Lorenzi, P., Opravil, M., Hirschel, B., Chave, J.-P., Furrer, H.-J., Sax, H., Vaclav Perneger, T., Perrin, L., Kaiser, L., & Yerly, S. (1999) · AIDS · doi:10.1097/00002030-199902040-00001 · Cited by 205
Robertson, J., Meier, M., Wall, J., Ying, J., & Fichtenbaum, C. J. (2006) · Clinical Infectious Diseases · doi:10.1086/503903 · Cited by 203
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients
Venkataramana, A., Pardo, C. A., McArthur, J. C., Kerr, D. A., Irani, D. N., Griffin, J. W., Burger, P., Reich, D. S., Calabresi, P. A., & Nath, A. (2006) · Neurology · doi:10.1212/01.wnl.0000227922.22293.93 · Cited by 182
De Clercq, E. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.241 · Cited by 163
A historical sketch of the discovery and development of HIV-1 integrase inhibitors
Savarino, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.12.1507 · Cited by 140
Costs of HIV medical care in the era of highly active antiretroviral therapy
Gebo, K. A., Chaisson, R. E., Folkemer, J. G., Bartlett, J. G., & Moore, R. D. (1999) · AIDS · doi:10.1097/00002030-199905280-00013 · Cited by 128
Gulick, R. M. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00570.x · Cited by 105
Truong, H. M., Grant, R. M., McFarland, W., Kellogg, T. A., Kent, C. K., Louie, B. E., Wong, E., & Klausner, J. D. (2006) · AIDS · doi:10.1097/01.aids.0000252059.85236.af · Cited by 78
Gathe, J., Cooper, D. A., Farthing, C., Jayaweera, D. T., Norris, D., Pierone, G., Steinhart, C. R., Trottier, B., Walmsley, S. L., Workman, C., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508353 · Cited by 76
Self-citationHIV transmission and primary drug resistance.
Turner, D., & Wainberg, M. A. (2006) · PubMed · Cited by 50
Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults
Temesgen, Z., Cainelli, F., Poeschla, E. M., Vlahakis, S., & Vento, S. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70550-3 · Cited by 39
Goldman, J. M. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.08.001 · Cited by 38
Youle, M. S., Staszweski, S., Clotet, B., Arribas, J. R., Blaxhult, A., Carosi, G., DeJesus, E., Perri, G. D., Estrada, V., Fisher, M., et al. (2006) · HIV Clinical Trials · doi:10.1310/2xvk-pbgl-735n-wh72 · Cited by 23
Self-citationHornberger, J. C., Kilby, J. M., Wintfeld, N., & Green, J. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.240 · Cited by 22
Knysz, B., Kuliszkiewicz-Janus, M., Jeleń, M., Podlasin, R. B., & Gładysz, A. (2006) · PubMed · Cited by 18
Immune reconstitution in HIV infection and its relationship to cancer
Robertson, P. L., & Scadden, D. T. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00047-9 · Cited by 12
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Self-citationApproved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Maraviroc for Previously Treated Patients with R5 HIV-1 Infection
Gulick, R. M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0803152 · Cited by 752
Self-citationAnti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.
De Clercq, E. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.10.010 · Cited by 627
Lennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625
Self-citation
Metadata
- Authors
- Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B.-Y., & Teppler, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-24
- Volume
- 359
- Issue
- 4
- Pages
- 339-354
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2150504993
- Cited by
- 691
- References
- 40
- FWCI
- 72.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.